Abstract
Among young persons, ease of use, high efficacy, and high acceptability makes the etonogestrel contraceptive implant an important choice for this age group. Adolescent-friendly, patient-centered counseling considers the patient's cognitive development, the influence of friends and family, as well as their own preferences and values. Age-appropriate language, graphics, and models are useful to explain contraceptive options and relevant side effects. Effectiveness, reversibility, safety, noncontraceptive benefits, and side effects are important attributes and should be discussed when teens are choosing a contraceptive method. In this review we describe suggested best practices for counseling adolescents about the etonogestrel implant so they can make informed, prudent decisions about using this contraceptive method.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 448-454 |
| Number of pages | 7 |
| Journal | Journal of Pediatric and Adolescent Gynecology |
| Volume | 33 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 1 2020 |
Funding
Dr Berlan is a Merck Nexplanon Clinical Trainer and Consultant to Merck, Bayer, and Ohio Chapter, American Academy of Pediatrics, and a reviewer for UptoDate (royalties received). Dr Richards is a Merck Nexplanon Clinical Trainer and Consultant to Merck. Dr Sales Vieira serves on Medical Advisory Boards and gives lectures for Bayer and Merck. Dr Kaunitz is a Consultant for Merck and Mithra, and an author for UpToDate (royalties received). His institution receives research monies from Abbvie, Merck, and Mithra, and has received travel reimbursement from American College of Obstetricians and Gynecologists and the Centers for Disease Control and Prevention for preparation of guidance regarding contraception and menopause. Dr Edelman is a consultant for Gynuity Health Projects, FHI360, and Nexplanon trainer for Merck (no monies accepted since 2016), and an author for UptoDate (royalties received). Her institution receives research monies from Merck, HRA Pharma, and the National Institutes of Health on projects for which she is principal investigator. These potential conflicts have been reviewed and managed by Oregone Health & Science University. She is the Chair of the American College of Obstetricians and Gynecologists Practice Bulletins for Gynecology committee and has received travel and honoraria from the American College of Obstetricians and Gynecologists. She is an expert technical consultant for the Centers for Disease Control and Prevention and the World Health Organization on reproductive health issues and has received travel reimbursement. Dr Creinin serves on an Advisory Board for Merck & Co and TherapeuticsMD, and is a consultant for Danco, Estetra Mayne, Medicines360, and Merck & Co. The Department of Obstetrics and Gynecology, University of California, Davis, receives research funding for contraceptive research from Daré, HRA Pharma, Medicines360, Merck & Co, and Sebela. Dr Mansour has served on an advisory board for Merck & Co, manufacturer of the etonogestrel implant, and has received financial support to attend pharmaceutical advisory board meetings, undertake research studies, speak at educational meetings, webinars, and conferences, along with travel grants from Bayer, Consilient Healthcare, Gedeon, Merck & Co, Mithra, Mylan, Pfizer, and Vifor Pharma. Dr Fraser indicated no conflicts of interest. Dr Berlan is a Merck Nexplanon Clinical Trainer and Consultant to Merck, Bayer, and Ohio Chapter, American Academy of Pediatrics, and a reviewer for UptoDate (royalties received). Dr Richards is a Merck Nexplanon Clinical Trainer and Consultant to Merck. Dr Sales Vieira serves on Medical Advisory Boards and gives lectures for Bayer and Merck. Dr Kaunitz is a Consultant for Merck and Mithra, and an author for UpToDate (royalties received). His institution receives research monies from Abbvie, Merck, and Mithra, and has received travel reimbursement from American College of Obstetricians and Gynecologists and the Centers for Disease Control and Prevention for preparation of guidance regarding contraception and menopause. Dr Edelman is a consultant for Gynuity Health Projects, FHI360, and Nexplanon trainer for Merck (no monies accepted since 2016), and an author for UptoDate (royalties received). Her institution receives research monies from Merck, HRA Pharma, and the National Institutes of Health on projects for which she is principal investigator. These potential conflicts have been reviewed and managed by Oregone Health & Science University. She is the Chair of the American College of Obstetricians and Gynecologists Practice Bulletins for Gynecology committee and has received travel and honoraria from the American College of Obstetricians and Gynecologists. She is an expert technical consultant for the Centers for Disease Control and Prevention and the World Health Organization on reproductive health issues and has received travel reimbursement. Dr Creinin serves on an Advisory Board for Merck & Co and TherapeuticsMD, and is a consultant for Danco, Estetra Mayne, Medicines360, and Merck & Co. The Department of Obstetrics and Gynecology, University of California, Davis, receives research funding for contraceptive research from Dar?, HRA Pharma, Medicines360, Merck & Co, and Sebela. Dr Mansour has served on an advisory board for Merck & Co, manufacturer of the etonogestrel implant, and has received financial support to attend pharmaceutical advisory board meetings, undertake research studies, speak at educational meetings, webinars, and conferences, along with travel grants from Bayer, Consilient Healthcare, Gedeon, Merck & Co, Mithra, Mylan, Pfizer, and Vifor Pharma. Dr Fraser indicated no conflicts of interest.
| Funders | Funder number |
|---|---|
| HRA Pharma | |
| Merck | |
| Nexplanon trainer for Merck | |
| Oregone Health & Science University | |
| Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health | |
| Centers for Disease Control and Prevention for fall prevention | FHI360 |
| American College of Obstetricians and Gynecologists | |
| Merck | |
| World Health Organization, SAGE | Medicines360 |
| American Academy of Pediatrics | |
| AbbVie | |
| Department of Obstetrics and Gynecology, University of Wisconsin-Madison | |
| Vifor Pharma |
Keywords
- Adolescent
- Etonogestrel
- Female
- Humans
- Patient-centered care
- Pregnancy
- Pregnancy in adolescence
- Progestins
- Unplanned pregnancy
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Obstetrics and Gynecology
Fingerprint
Dive into the research topics of 'Best Practices for Counseling Adolescents about the Etonogestrel Implant'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS